Therapeutic effects of Zymomonas mobilis on experimental DSS-Induced colitis mouse model

• Main Author: Almo, Manuela Maragno do
• Publication Date: 2023
• Other Authors: Sousa, Isabel Garcia, Olinto, Vitor Guimarães, Pinhate, Sylvia Barbosa, Jivago, José Luiz de Paula Rôlo, Sousa, Davi Emanuel Ribeiro de, Castro, Márcio Botelho de, Rubini, Marciano Régis, Maranhão, Andrea Queiroz, Brigido, Marcelo Macedo
• Format: Article
• Language: eng
• Source: Repositório Institucional da UnB
• Download full: http://repositorio.unb.br/handle/10482/50649; https://doi.org/10.3390/microorganisms11112793; https://orcid.org/0000-0002-0361-7730; https://orcid.org/0000-0002-6326-9803; https://orcid.org/0000-0003-1237-0693; https://orcid.org/0000-0002-3996-0856; https://orcid.org/0000-0002-1946-7191; https://orcid.org/0000-0002-7136-7059
• topic: Bactérias; Colite; Microbiota; Imunomodulação; Probióticos

Zymomonas mobilis, a Gram-negative bacteria observed in some popular beverages, is considered safe and has been studied for its potential therapeutic benefits. In this study, we explored its effects on the inflammatory process, tissue integrity, differential gene expression, and microbiota composition in an experimental dextran sulfate sodium (DSS)-induced colitis model in mice. As a result, Z. mobilis alleviated the symptoms caused by DSS administration, as indicated by reduced weight loss, disease activity index, a significant reduction in the colon weight/length ratio, and histopathological improvement. Also, Z. mobilis could restore the mucosal barrier as well as increase the expression of Muc3 and Ocln genes. An analysis of 16S rRNA sequences showed that Z. mobilis alters gut microbiota, increasing Akkermansia muciniphila abundance and decreasing Escherichia coli. Furthermore, Z. mobilis seems to be involved in potentiating a regulatory phenotype by inducing immunomodulatory genes like Tgfb, Il5, Il10, and Foxp3 and reducing the relative mRNA expression of proinflammatory cytokines TNF, Il6, and Il17. Our data suggest that Z. mobilis could alleviate disease progression and be considered a possible probiotic adjuvant for pathologies of the bowel.